Articles tagged with Acquired Immune Deficiency Syndrome
Population growth is expected to double in Africa by 2050, posing a significant threat to poverty reduction. Experts argue that continued high fertility rates and rapid population growth could be more serious obstacles to development than AIDS, threatening food security and increasing dependence on international assistance.
Dr. Henry Gabelnick, a renowned expert in reproductive health and microbicide development, has been awarded the lifetime achievement award by International Conference on AIDS India. The award recognizes his significant contributions to the field, including the development of Ushercell, a microbicide consisting of cellulose sulfate.
A multi-center study of 425 HIV-positive men found that central fat loss was statistically associated with peripheral fat loss in HIV-positive men on retroviral therapy. Central fat gain was also less among HIV-positive men, with age being the strongest factor associated with increased visceral fat.
Researchers found that AIDS selectively attacks the brain's motor, language and judgment centers, but leaves other areas intact. Brain scans revealed specific patterns of tissue damage correlated with physical and mental symptoms, including impaired motor coordination and slowed reflexes.
A community-level intervention program targeting young adolescents delays early intercourse, increases condom use, and reduces high-risk sexual behavior. The program successfully delayed sexual debut and increased condom use among participants.
The American Society for Clinical Pathology is providing laboratory training and quality improvement programs for diagnosis and monitoring of HIV/AIDS patients in resource-limited countries. The program aims to improve the effectiveness of HIV diagnostic, care, and treatment services and interventions.
Researchers have discovered an unexpected connection between the feline immunodeficiency virus (FIV) and HIV, which may lead to the development of a new HIV vaccine. FIV, also known as feline AIDS, has been used in animal studies to model human AIDS, but this study found that a core protein from HIV also protects cats against FIV.
A study of over 3,200 HIV patients found that HAART substantially reduces the rate of AIDS progression by 86% compared to no treatment. The effectiveness of HAART increases with time since initiation, but its benefits are reduced for patients who contracted HIV through intravenous drug use.
Researchers criticize activist groups for derailing PREP trials, citing concerns about drug's efficacy and safety. The pause in trials may hinder development of female-controlled prevention technologies.
Global HIV/AIDS cases are increasing worldwide, with Africa being only one of the regions affected. The Lancet study highlights the need for international cooperation and resource allocation to address this growing epidemic.
Poorer people have been left out of past aid programs due to insufficient planning, and donors and developing countries should learn from these mistakes. Local health officials must decide who will receive therapy and live, and who will go without, despite growing demand and limited supply.
Women now account for nearly half of the 40 million people worldwide infected with HIV, a significant shift from the early days of the pandemic. The increased number of female cases is attributed to various factors, including heterosexual transmission and cultural influences.
Khalili will investigate the molecular mechanisms causing JC virus reactivation in AIDS patients, which can lead to the fatal disease PML. The researcher aims to understand how HIV triggers JC virus infections and develop new treatments for demyelinating diseases like MS.
A Stanford study found that early treatment of asymptomatic HIV-infected infants can delay disease progression and enhance survival. The research, which followed nearly 200 children over 17 years, showed that treatment made a significant difference in preventing or delaying the progression of the disease.
A recent study published in the American Journal of Preventive Medicine reveals a concerning trend: alcohol-impaired driving episodes are increasing, with four out of five cases linked to binge drinking. The researchers stress that new strategies are needed to address this issue, including reducing binge drinking and implementing deter...
A patient with a drug-resistant form of HIV was identified, exhibiting rapid progression to AIDS. The case highlights the need for intensified prevention efforts, particularly among high-risk groups such as men who have sex with men and intravenous drug users.
A large multicohort study of HAART-naive patients found significant reductions in AIDS incidence and opportunistic events, with greater declines for viral etiologies.
A study in Senegal found that migrants' social context influences their sexual behavior and risk of HIV transmission. In rural areas, strict social control and religion may encourage migrants to adopt safer sex practices upon return. The study suggests that migration is not a major contributor to HIV spread in Senegal.
UCLA researchers develop gene therapy approach using modified HIV to target P-glycoproteins on cancer cells, minimizing side effects and maximizing therapeutic effectiveness. The method shows promise for controlling cancer and other diseases.
A study has identified a genetic factor that determines an individual's susceptibility to HIV/AIDS. The research found that people with fewer copies of the CCL3L1 gene are more likely to contract HIV and experience rapid disease progression, while those with more copies are less prone to infection.
The Global HIV/AIDS Clinical Training Materials Database provides adaptable clinical training materials tailored for international settings. The database bridges the information gap in countries hardest hit by the AIDS epidemic by adapting existing resources.
The St. Petersburg/New Haven Partnership aims to develop a community-wide HIV/AIDS care program in Russia, with training and exchanges between American and Russian health professionals. Led by Yale's Krystn Wagner and Robert Heimer, the partnership seeks to improve HIV/AIDS care and treatment in Russia.
The study found that HAART reduced mortality in HIV-infected injection drug users with high CD4 cell counts, similar to those without HIV. Initiating or switching to HAART at higher CD4 counts than current recommendations may improve outcomes for asymptomatic patients.
Researchers discovered a critical link in the molecular pathway that enables the immune system to target invaders with precision. The discovery may also provide new information on lymphoma, a type of leukemia where certain immune cells proliferate uncontrollably.
A UCLA study found that HIV-coping programs for families with infected parents reduced dropout rates, teenage pregnancy, and public welfare claims among children. The program also improved mental health outcomes and social relationships.
The Lancet editorial argues that criticism of President Bush's AIDS spending is necessary to ensure efficient use of limited resources. Leading scientists and public-health advocates have judged that the size of US investment into AIDS renders President Bush immune from criticism, but this assessment is mistaken.
The HIV Structural Reference Database will aid in developing strategies to inhibit HIV protease activity and understand mutations that make the virus resistant to certain drugs. The database contains annotated structural data from published literature and laboratory contributions.
Young men in rural Malawi associate HIV with masculinity and engage in risky behavior to demonstrate virility. This misunderstanding of AIDS risk has significant implications for future research and HIV prevention education.
Researchers at Michigan State University have devised new ways to understand the impact of AIDS on families in rural Africa. The study shows that the disease is not always devastating, but rather cripples some families while leaving others with a better chance of enduring.
The Global Fund's performance-based payment system is challenging for recipients and sub-recipients to meet, hindering disease control intervention scaling-up. Experts call for clearer guidelines, improved coordination among donors, and simpler funding systems to achieve the Fund's goals.
The UCSF Center for HIV Information has released the third edition of a CD-ROM targeting healthcare professionals in developing countries. The resource includes 5,000 pages of text on treatments, drugs, and standards of care from various countries.
Nigerian naval personnel are putting themselves and their partners at risk by denying the existence of AIDS and engaging in risky sexual behaviors. A recent survey found that nearly half of sailors had sex with a female sex worker without using a condom, despite having good knowledge of AIDS-related information.
A new study will evaluate the effectiveness of a face-to-face support group for older adults with depression and HIV/AIDS. The intervention aims to improve coping mechanisms, quality of life, and social support.
New guidelines suggest FUZEON is an important treatment for HIV drug resistance, offering clear advice on timing of initiation and patient support. The guidelines aim to enable more pre-treated patients to benefit from FUZEON therapy.
Researchers found that patients taking prednisolone had significantly higher CD4+ T-cell counts after two years compared to those not taking the drug. After five years, over 10% of patients on prednisolone maintained high CD4+ T-cell counts.
A recent study found that HIV infection progresses to AIDS at a rate of 7.4 years in developing countries, compared to 11 years in Western developed nations. The study also revealed a higher mortality rate among men living in developing countries.
A study found that HIV-positive US military personnel who received a smallpox vaccine between 2002-2003 showed no negative effects. The researchers suggest exempting HIV-infected individuals from vaccination during outbreaks, but consider weakened vaccines for immunocompromised people in the future.
Researchers found that dual-infection with HIV and GBV-C leads to better outcomes, including slower progression to AIDS and lower mortality rates. Understanding the mechanism behind this phenomenon could lead to the development of improved therapies.
Researchers at UW-Madison find that mutations allowing AIDS viruses to escape immune detection also hinder their ability to grow after transmission. The discovery may help design vaccines targeting the virus's most vulnerable spots.
A study by Case Western Reserve University researchers found that human beta defensins 2 and 3 in the mouth's lining can inhibit HIV-1 replication and regulate viral receptors. This discovery has potential for developing new medical interventions using natural products to prevent HIV infection, particularly in high-risk areas.
A laboratory study found that methylnaltrexone blocked increases in HIV entry and replication when immune cells are exposed to therapeutic doses of morphine. The study suggests that the drug may improve care for patients with AIDS who require pain relief, potentially reducing the risk of severe constipation.
Researchers found that total lymphocyte count and hemoglobin concentration decline rapidly in individuals who develop AIDS, with over 77% of study participants exhibiting these declines. This finding offers an alternative to current HIV diagnosis methods, which require expensive technology and equipment.
Purdue University chemist Jean Chmielewski has won a national award for developing new compounds that disrupt the AIDS virus's ability to reproduce. Her approach involves creating molecular 'wedges' that block HIV proteins from binding together, promising initial results in testing with infected cells.
Researchers found that the HIV vpr gene exploits the normal repair process of cells to stop vital white blood cells from replicating, thus disabling the immune system. The study suggests a possible treatment for AIDS-related immune-system damage using medicines that prevent the human ATR gene from being activated by HIV's vpr gene.
Researchers have developed a new herpes-based AIDS vaccine that could help the immune system produce more infection-fighting antibodies and killer T-cells, potentially making it more effective. The vaccine uses an amplicon to deliver DNA from the AIDS virus, which is then amplified and used to trigger an immune response.
A study published in the journal AIDS found that HAART therapy can significantly prolong survival for AIDS patients with central nervous system lymphoma, with median survival of at least 22 months. This is a significant finding, as previously diagnosed patients had only a few weeks to months after diagnosis.
The WHO 2003-2008 programme focuses on controlling HIV/AIDS, with a goal of 3 million people in developing countries receiving antiretroviral treatment by 2005. The initiative also aims to strengthen health systems and secure political backing for investment.
The Lancet appoints Dr. Tobias to a $15 billion programme tackling AIDS in African and Caribbean countries most devastated by the pandemic. Critics argue that his lack of knowledge about Africa and connections to the pharmaceutical industry may compromise his credibility.
A study of 9800 patients in Europe, Israel, and Argentina found that HAART significantly reduced AIDS incidence by 50%, with a 40% reduction in deaths among patients with low CD4 counts. Long-term follow-up is essential to observe changing causes of morbidity and mortality.
Researchers at USC successfully simulated the somatic hypermutation process in vitro, closely mirroring its natural occurrence. This breakthrough enables the development of an in vitro system that can mimic the body's immune response.
A study by Northwestern University found that juvenile detainees aged 10-18 engage in significantly higher rates of HIV-risk behaviors, with 95% exhibiting multiple sexual and drug risks. Boys were more likely to engage in riskier behaviors, while girls aged 16+ were more active sexually.
The Vanderbilt Meharry Developmental Center for AIDS Research aims to advance treatment and prevention of HIV/AIDS through collaboration and education. The center will focus on racial disparities and minority populations, building on existing collaborations between the two institutions.
Researchers identify a helpful gene mutation in the Vpr gene of long-term nonprogressive HIV patients, which impairs the HIV virus' cell-killing machinery. The presence or absence of this mutation may play a central role in determining which patients develop fatal AIDS.
A study found that HAART reduced the risk of visual impairment and improved quality of life for AIDS patients. Patients who received HAART had a lower incidence of visual acuity loss compared to those who did not, especially those with substantial improvement in their immunity.
The editorial emphasizes that providing affordable drugs is insufficient to combat HIV in the developing world. Comprehensive medical care, including training for healthcare workers and laboratory tests, must also be included to make Highly Active Antiretroviral Therapy (HAART) effective.
A study of over 300 HIV patients found that 32% reported better life after diagnosis, with fewer worries about finances or disclosure. Patients who said life was better expressed more optimism and participated in non-organized religious activities.
The study reveals how B cell lymphocytes assemble genes to encode specific classes of antibodies, including IgA, IgE, and IgG. The findings also explain the role of activation-induced cytidine deaminase (AID) in initiating gene specialization, a process crucial for the immune response.
Researchers studied sooty mangabey monkeys infected with SIV, finding they didn't get sick like humans with HIV. The lack of symptoms was attributed to low-level immune system responses and ability to maintain T cell renewal.
The US has pledged $1 billion to combat HIV/AIDS in 14 high-prevalence countries. The programme aims to prevent 7 million new infections, treat 2 million people, and support 10 million infected individuals.
The NIH has awarded nearly $8 million to the University of Pittsburgh and Magee-Womens Research Institute to develop a microbicide barrier to prevent HIV transmission in women. The project aims to create a safe and effective way for women to protect themselves against sexually transmitted infections, including HIV.